Advertisement

International Ophthalmology

, Volume 38, Issue 5, pp 1947–1953 | Cite as

Upregulated IRAK1 and IRAK4 promoting the production of IFN-γ and IL-17 in Behcet’s disease

  • Min Sun
  • Peizeng Yang
  • Yan Yang
  • Jian Ye
Original Paper
  • 218 Downloads

Abstract

Purpose

To investigate the expression and function of IRAK1 and IRAK4 involved in the development of Behcet’s disease.

Methods

Twenty-eight Behcet’s patients and thirty-two normal subjects were involved in this study. The mRNA levels of IRAK1 and IRAK4 from active Behcet’s patients, inactive Behcet’s patients and normal controls were detected using real-time quantitative PCR. CD4+T cells were extracted from peripheral blood mononuclear cells of active Behcet’s patients and normal controls. After coculturing IRAK1/4 inhibitor with CD4+T cells in the presence of rIL-18 protein or rIL-1β protein for 3 days, the proliferation of CD4+T cells was measured using a modified MTT assay. Meanwhile, the levels of IFN-γ and IL-17 were detected by enzyme-linked immunosorbent assay.

Results

The mRNA levels of IRAK1 and IRAK4 were both significantly increased in active Behcet’s patients compared with those of inactive Behcet’s patients and normal subjects. However, there was no difference of IRAK1 mRNA level or the IRAK4 mRNA level between the inactive Behcet’s patients and normal controls. After coculturing with IRAK1/4 inhibitor, the proliferation of the CD4+T cells was inhibited both in active Behcet’s patients and in normal controls. Meanwhile, the expression of IFN-γ and IL-17 was also suppressed by IRAK1/4 inhibitor both in active Behcet’s patients and in normal subjects.

Conclusion

The high mRNA levels of IRAK1 and IRAK4 were correlated with the development of Behcet’s disease, which suggested that IRAK1 and IRAK4 might participate in the pathogenesis of Behcet’s disease. The inhibitory function of IRAK1/4 inhibitor prompts that it may be a new therapeutic target for treating this blindness disease.

Keywords

IRAK1 IRAK4 Behcet’s disease 

Notes

Acknowledgements

This study was supported by National Natural Science Foundation Project Grant 81200679. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Compliance with ethical standards

Conflict of interest

All authors declare that he/she has no conflict of interest.

Ethical approval

All procedures performed in studies were in accordance with the ethical standards of the Ethics Committee of the Third Affiliated Hospital of the Third Military Medical University and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L et al (2001) Revised diagnostic criteria for Vogt–Koyanagi–Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 131(5):647–652CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM et al (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6(11):1123–1132CrossRefGoogle Scholar
  3. 3.
    Cao Z, Henzel WJ, Gao X (1996) IRAK: a kinase associated with the interleukin-1 receptor. Science 271(5252):1128–1131CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Li S, Strelow A, Fontana EJ, Wesche H (2002) IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci U S A 99(8):5567–5572CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Gottipati S, Rao NL, Fung-Leung WP (2008) IRAK1: a critical signaling mediator of innate immunity. Cell Signal 20(2):269–276CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Deng C, Radu C, Diab A, Tsen MF, Hussain R, Cowdery JS et al (2003) IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity. J Immunol 170(6):2833–2842CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Kanakaraj P, Ngo K, Wu Y, Angulo A, Ghazal P, Harris CA et al (1999) Defective interleukin (IL)-18-mediated natural killer and T helper cell type 1 responses in IL-1 receptor-associated kinase (IRAK)-deficient mice. J Exp Med 189(7):1129–1138CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Jeong JJ, Jang SE, Hyam SR, Han MJ, Kim DH (2014) Mangiferin ameliorates colitis by inhibiting IRAK1 phosphorylation in NF-kappaB and MAPK pathways. Eur J Pharmacol 740:652–661CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Xia P, Fang X, Zhang ZH, Huang Q, Yan KX, Kang KF et al (2012) Dysregulation of miRNA146a versus IRAK1 induces IL-17 persistence in the psoriatic skin lesions. Immunol Lett 148(2):151–162CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C et al (2002) Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 416(6882):750–756CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, Yang K et al (2003) Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299(5615):2076–2079CrossRefGoogle Scholar
  12. 12.
    Kawagoe T, Sato S, Jung A, Yamamoto M, Matsui K, Kato H et al (2007) Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling. J Exp Med 204(5):1013–1024CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Yang P, Fang W, Meng Q, Ren Y, Xing L, Kijlstra A (2008) Clinical features of chinese patients with Behcet’s disease. Ophthalmology 115(2):312.e4–318.e4CrossRefGoogle Scholar
  14. 14.
    de Smet MD, Dayan M (2000) Prospective determination of T-cell responses to S-antigen in Behcet’s disease patients and controls. Invest Ophthalmol Vis Sci 41(11):3480–3484PubMedPubMedCentralGoogle Scholar
  15. 15.
    Yamamoto JH, Minami M, Inaba G, Masuda K, Mochizuki M (1993) Cellular autoimmunity to retinal specific antigens in patients with Behcet’s disease. Br J Ophthalmol 77(9):584–589CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K (2002) Cytokine profile in Behcet’s disease patients. Relationship with disease activity. Scand J Rheumatol 31(4):205–210CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Chi W, Yang P, Zhu X, Wang Y, Chen L, Huang X et al (2010) Production of interleukin-17 in Behcet’s disease is inhibited by cyclosporin A. Mol Vis 16:880–886PubMedPubMedCentralGoogle Scholar
  18. 18.
    Sun M, Yang P, Du L, Yang Y, Ye J (2014) The role of interleukin-1 receptor-associated kinases in Vogt–Koyanagi–Harada disease. PLoS ONE 9(4):e93214CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Criteria for diagnosis of Behcet’s disease (1990) International Study group for Behcet’s disease. Lancet 335(8697):1078–1080Google Scholar
  20. 20.
    Patra MC, Choi S (2016) Recent progress in the molecular recognition and therapeutic importance of interleukin-1 receptor-associated kinase 4. Molecules 21(11):E1529CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Talreja J, Talwar H, Ahmad N, Rastogi R, Samavati L (2016) Dual inhibition of Rip2 and IRAK1/4 regulates IL-1beta and IL-6 in sarcoidosis alveolar macrophages and peripheral blood mononuclear cells. J Immunol 197(4):1368–1378CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Lakoski SG, Li L, Langefeld CD, Liu Y, Howard TD, Brosnihan KB et al (2007) The association between innate immunity gene (IRAK1) and C-reactive protein in the diabetes heart study. Exp Mol Pathol 82(3):280–283CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Thomas JA, Haudek SB, Koroglu T, Tsen MF, Bryant DD, White DJ et al (2003) IRAK1 deletion disrupts cardiac Toll/IL-1 signaling and protects against contractile dysfunction. Am J Physiol Heart Circ Physiol 285(2):H597–H606CrossRefPubMedCentralGoogle Scholar
  24. 24.
    Valaperti A, Nishii M, Liu Y, Naito K, Chan M, Zhang L et al (2013) Innate immune interleukin-1 receptor-associated kinase 4 exacerbates viral myocarditis by reducing CCR5(+) CD11b(+) monocyte migration and impairing interferon production. Circulation 128(14):1542–1554CrossRefPubMedCentralGoogle Scholar
  25. 25.
    Yazici H (2004) The lumps and bumps of Behcet’s syndrome. Autoimmun Rev 3(Suppl 1):S53–S54PubMedPubMedCentralGoogle Scholar
  26. 26.
    Guenane H, Hartani D, Chachoua L, Lahlou-Boukoffa OS, Mazari F, Touil-Boukoffa C (2006) Production of Th1/Th2 cytokines and nitric oxide in Behcet’s uveitis and idiopathic uveitis. J Fr Ophtalmol 29(2):146–152CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2017

Authors and Affiliations

  1. 1.Department of Ophthalmology, Research Institute of Surgery and Daping HospitalThird Military Medical UniversityChongqingPeople’s Republic of China
  2. 2.Chongqing Key Laboratory of Ophthalmology, Chongqing Eye InstituteThe First Affiliated Hospital of Chongqing Medical UniversityChongqingPeople’s Republic of China

Personalised recommendations